» Articles » PMID: 15692810

Markers of Inflammation Are Cross-sectionally Associated with Microvascular Complications and Cardiovascular Disease in Type 1 Diabetes--the EURODIAB Prospective Complications Study

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2005 Feb 5
PMID 15692810
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: The pathogenesis of vascular complications in type 1 diabetes is poorly understood, but may involve chronic, low-grade inflammation. We investigated the association of markers of inflammation with vascular complications in type 1 diabetes.

Methods: A cross-sectional nested case-control study of the follow-up data of the EURODIAB Prospective Complications Study. This study included 543 individuals (278 men) with type 1 diabetes diagnosed at <36 years of age. Cases (n=348) had complications of diabetes, controls (n=195) had no complications.

Results: C-reactive protein, interleukin-6 and tumour necrosis factor-alpha levels, which were combined in an inflammatory marker Z-score, were associated with albuminuria, retinopathy and cardiovascular disease. Calculated means (95% confidence intervals) of the marker Z-score were -0.15 (-0.22 to -0.07), 0.10 (-0.05 to 0.25), and 0.28 (0.15 to 0.41), p for trend <0.0001, in individuals with normo-, micro- and macroalbuminuria; -0.23 (-0.33 to -0.13), 0.14 (0.02 to 0.25) and 0.20 (0.07 to 0.32), p for trend <0.0001, in individuals with no, non-proliferative and proliferative retinopathy; and -0.28 (-0.39 to -0.18) and 0.06 (-0.08 to 0.20), p<0.001, in individuals without and with cardiovascular disease. Per 1 SD increase of the inflammatory marker Z-score, GFR decreased by -4.6 (-6.6 to -2.6) ml per min per 1.73 m(2) (p<0.001).

Conclusions/interpretation: We have shown that markers of inflammation are strongly and independently associated with microvascular complications and cardiovascular disease in type 1 diabetes. These data suggest that strategies to decrease inflammatory activity may help to prevent the development of vascular complications in type 1 diabetes.

Citing Articles

Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications.

van Heck J, Ajie M, Joosten L, Tack C, Stienstra R Diabetes Obes Metab. 2024; 27(2):719-728.

PMID: 39562286 PMC: 11701194. DOI: 10.1111/dom.16066.


Severe hypoglycaemia-induced microglial inflammation damages microvascular endothelial cells, leading to retinal destruction.

Hu Y, Li Z, Li H, Xu Q, Xu C, Lin W Diab Vasc Dis Res. 2024; 21(4):14791641241278506.

PMID: 39187253 PMC: 11348349. DOI: 10.1177/14791641241278506.


Distinct association patterns of chemokine profile and cardiometabolic status in children and adolescents with type 1 diabetes and obesity.

Spehar Uroic A, Filipovic M, Sucur A, Kelava T, Kovacic N, Grcevic D Front Endocrinol (Lausanne). 2024; 15:1335371.

PMID: 39109081 PMC: 11300205. DOI: 10.3389/fendo.2024.1335371.


Serum MicroRNA-191-5p Levels in Vascular Complications of Type 1 Diabetes: The EURODIAB Prospective Complications Study.

Bellini S, Guarrera S, Matullo G, Schalkwijk C, Stehouwer C, Chaturvedi N J Clin Endocrinol Metab. 2023; 109(1):e163-e174.

PMID: 37552780 PMC: 10735284. DOI: 10.1210/clinem/dgad468.


Prediction model of delayed graft function based on clinical characteristics combined with serum IL-2 levels.

Zhao S, Liu Y, Zhou C, Chen Z, Cai Z, Han J BMC Nephrol. 2022; 23(1):284.

PMID: 35971094 PMC: 9377118. DOI: 10.1186/s12882-022-02908-2.


References
1.
Kohner E, Patel V, Rassam S . Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes. 1995; 44(6):603-7. DOI: 10.2337/diab.44.6.603. View

2.
Limb G, Hollifield R, Webster L, Charteris D, CHIGNELL A . Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci. 2001; 42(7):1586-91. View

3.
. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994; 37(3):278-85. DOI: 10.1007/BF00398055. View

4.
Forbes J, Soulis T, Thallas V, Panagiotopoulos S, Long D, Vasan S . Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001; 44(1):108-14. DOI: 10.1007/s001250051587. View

5.
Schalkwijk C, Poland D, van Dijk W, Kok A, Emeis J, Drager A . Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999; 42(3):351-7. DOI: 10.1007/s001250051162. View